VRTX:NGS-Vertex Pharmaceuticals Incorporated (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 439.62

Change

0.00 (0.00)%

Market Cap

USD 21.38B

Volume

1.65M

Analyst Target

USD 306.43
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

+8.92 (+1.32%)

USD 78.92B
ARGX argenx NV ADR

-0.12 (-0.02%)

USD 39.62B
ALNY Alnylam Pharmaceuticals Inc

-2.03 (-0.73%)

USD 30.22B
MRNA Moderna Inc

+0.24 (+0.58%)

USD 18.29B
RPRX Royalty Pharma Plc

+0.66 (+2.12%)

USD 18.12B
SMMT Summit Therapeutics PLC

-0.24 (-1.01%)

USD 17.52B
UTHR United Therapeutics Corporatio..

-1.27 (-0.34%)

USD 15.91B
INCY Incyte Corporation

+0.05 (+0.07%)

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

+0.07 (+0.11%)

USD 12.74B
INSM Insmed Inc

-0.85 (-1.08%)

USD 12.50B

ETFs Containing VRTX

DCCHAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

-0.52 (-2.20%)

USD 0.08B
DCUSAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

-0.97 (-2.20%)

N/A
DCEUAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

-0.19 (-2.20%)

N/A
DCGBAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 10.72 % 0.35 %

+1.40 (+-2.20%)

USD 0.40B
MSGR 8.22 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 7.99 % 0.00 %

-0.05 (-2.20%)

N/A
BTEC:SW iShares Nasdaq US Biotech.. 7.95 % 0.00 %

+0.07 (+-2.20%)

N/A
CURG:LSE VanEck Genomics and Healt.. 7.45 % 0.00 %

-0.03 (-2.20%)

USD 4.94M
UBIO 6.52 % 0.95 %

N/A

N/A
LIFE-B:CA Evolve Global Healthcare .. 5.49 % 0.00 %

+0.14 (+-2.20%)

N/A
ZWHC:CA BMO Covered Call Health C.. 5.16 % 0.00 %

N/A

N/A
LIFE-U:CA Evolve Global Healthcare .. 5.00 % 0.00 %

+0.93 (+-2.20%)

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.94 % 0.00 %

+0.09 (+-2.20%)

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.91 % 0.00 %

+0.08 (+-2.20%)

N/A
XNNS:LSE Xtrackers MSCI Innovation.. 4.83 % 0.00 %

-0.66 (-2.20%)

N/A
XNNV:LSE Xtrackers MSCI Innovation.. 4.83 % 0.00 %

-0.85 (-2.20%)

N/A
XNNV:XETRA Xtrackers MSCI Innovation.. 4.76 % 0.00 %

-0.79 (-2.20%)

N/A
ZPW:CA BMO US Put Write ETF 3.47 % 0.71 %

-0.14 (-2.20%)

CAD 0.07B
HEAL:CA 3.39 % 0.00 %

N/A

N/A
CDNA:CA CI Bio-Revolution Index E.. 2.95 % 0.00 %

N/A

CAD 6.46M
BIOT:SW L&G Pharma Breakthrough U.. 2.68 % 0.00 %

+0.06 (+-2.20%)

N/A
UPWD 2.43 % 0.00 %

N/A

N/A
POWA Invesco Bloomberg Pricing.. 2.11 % 0.00 %

N/A

N/A
CAPG:CA Capital Group Global Equi.. 1.94 % 0.00 %

-0.59 (-2.20%)

CAD 0.04B
XLVE:CA 1.93 % 0.00 %

N/A

N/A
QQXT First Trust NASDAQ-100 Ex.. 1.89 % 0.60 %

+0.29 (+-2.20%)

USD 0.11B
FLXU:SW Franklin U.S. Equity UCIT.. 1.17 % 0.00 %

-0.63 (-2.20%)

N/A
THNZ:XETRA L&G Global Thematic ESG E.. 1.03 % 0.00 %

-0.18 (-2.20%)

N/A
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+0.90 (+-2.20%)

USD 0.06B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.23 (-2.20%)

USD 3.67M
DEF 0.00 % 0.59 %

N/A

N/A
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+0.01 (+-2.20%)

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

+1.07 (+-2.20%)

USD 6.25B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

-0.03 (-2.20%)

USD 0.06B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

+0.37 (+-2.20%)

USD 0.77B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+0.43 (+-2.20%)

N/A
SDG iShares MSCI Global Impac.. 0.00 % 0.49 %

-0.32 (-2.20%)

USD 0.19B
ZPW-U:CA BMO US Put Write ETF 0.00 % 0.00 %

-0.06 (-2.20%)

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.05 (+-2.20%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.04 (+-2.20%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+11.15 (+-2.20%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.04 (+-2.20%)

N/A
VLQ:CA 0.00 % 0.40 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+0.15 (+-2.20%)

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

-1.03 (-2.20%)

N/A
HWWA:LSE HSBC Multi Factor Worldwi.. 0.00 % 0.00 %

-0.36 (-2.20%)

N/A
SMRG:LSE 0.00 % 0.00 %

N/A

N/A
SMRU:LSE Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

N/A
HWWD:LSE HSBC Multi Factor Worldwi.. 0.00 % 0.00 %

-0.45 (-2.20%)

N/A
VMOM:LSE 0.00 % 0.00 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

+0.01 (+-2.20%)

USD 0.52B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.06 (+-2.20%)

N/A
FLXU:F Franklin LibertyShares IC.. 0.00 % 0.00 %

N/A

N/A
SM8T:F Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

N/A
XAIN:F Xtrackers - MSCI Indonesi.. 0.00 % 0.00 %

-0.23 (-2.20%)

USD 0.04B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.04 (+-2.20%)

USD 0.52B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+0.09 (+-2.20%)

USD 0.02B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
ZINN:CA 0.00 % 0.00 %

N/A

N/A
NVQ 0.00 % 0.00 %

N/A

N/A
CBUF:XETRA iShares MSCI World Health.. 0.00 % 0.00 %

+0.11 (+-2.20%)

USD 1.13B
TDOC:CA TD Global Healthcare Lead.. 0.00 % 0.00 %

+0.33 (+-2.20%)

CAD 0.09B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

+0.17 (+-2.20%)

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.17% 74% C 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.17% 74% C 79% B-
Trailing 12 Months  
Capital Gain 2.20% 66% D+ 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.20% 66% D+ 47% F
Trailing 5 Years  
Capital Gain 89.52% 88% B+ 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 89.52% 88% B+ 82% B
Average Annual (5 Year Horizon)  
Capital Gain 16.44% 62% D 70% C-
Dividend Return 16.44% 62% D 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.89% 90% A- 67% D+
Risk Adjusted Return 61.12% 97% N/A 83% B
Market Capitalization 21.38B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 32.57 21% 30%
Price/Book Ratio 6.69 21% 19%
Price / Cash Flow Ratio 29.64 3% 11%
Price/Free Cash Flow Ratio 192.53 1% 2%
Management Effectiveness  
Return on Equity -2.98% 94% 55%
Return on Invested Capital 22.53% 87% 89%
Return on Assets 12.05% 98% 96%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.